Abstract: A scleral plug which releases a drug accurately in a specified amount. The scleral plug is formed from a blend of a high-molecular weight polylactic acid having a molecular weight of 40,000 or higher and a low-molecular weight polylactic acid having a molecular weight of 40,000 or lower, and contains a drug for treating or preventing a vitreoretinal disease. The high-molecular weight polylactic acid and the low-molecular weight polylactic acid are in a blending ratio of preferably 90/10 to 50/50, more preferably 90/10 to 70/30, and most preferably 80/20. The molecular weight of the high-molecular weight polylactic acid is preferably 40,000 to 200,000. The molecular weight of the low-molecular weight polylactic acid is preferably 3,000 to 40,000, and more preferably 5,000 to 20,000. The drug is, for example, an antiulcer agent, an antiviral agent, an anti-inflammatory agent, an antifungal agent or an antimicrobial.

Abstract: An object of the present invention is to provide an aqueous solution of lactoferrin which can be preserved for a long period of time. The aqueous preparation according to the present invention is an aqueous preparation which is characterized by containing a polyvalent inorganic or organic acid or a salt thereof whereby stability of lactoferrin is improved and is an aqueous preparation in which concentration of the polyvalent inorganic or organic acid or a salt thereof is 0.005% (w/v) or more. In the case of ophthalmic solutions, for example, the polyvalent inorganic or organic acid or a salt thereof is preferably 0.01-3.0% (w/v), particularly preferably 0.1-1.0% (w/v).

Abstract: The present invention provides a technique enabling a drug of protein derivatives such as an interferon-&bgr; to be effectively applied to intraocular diseases such as diseases of a vitreous body, retina, and the like. Namely, the present invention provides a composition comprising a drug of protein derivatives adsorbed on a surface of fine particles of a lactic acid copolymer, and also a scleral plug formed from the composition. The average diameter of the fine particles is less than 1,000 nanometers, preferably within a range of 50 to 500 nanometers. The drug of protein derivatives is, for example, an interferon, particularly an interferon-&bgr;. The lactic acid copolymer preferably comprises lactic acid units and glycolic acid units.

Abstract: This invention relates to the compounds of the formula [I] which are useful for the treatment of cataracts, and the synthetic intermediates of the formula [II], ##STR1## wherein R.sup.1 is hydroxy which can be protected by a hydroxy protective group;R.sup.2 is lower alkyl;R.sup.3 is hydrogen, lower alkyl, hydroxy, which can be protected by a hydroxy protective group, or lower alkoxy, and the said lower alkyl can be substituted by hydroxy, which can be protected by a hydroxy protective group, amino or lower alkylamino;R.sup.4 is carboxy which can be converted into ester or amide; tetrazolyl; phosphono which can be converted into ester or amide; or sulfonyl which can be converted into ester or amide;R.sup.5 is cyano or lower alkoxy;A is alkylene;B is C.dbd.O, C.dbd.S or CH.sub.2, andis single bond or double bond.

Abstract: This invention relates to the compounds of the formula [I] which are useful for the treatment of cataracts, and the synthetic intermediates of the formula [II], ##STR1## wherein R.sup.1 is hydroxy which can be protected by a protective group;R.sup.2 is lower alkyl;R.sup.3 is hydrogen, lower alkyl, hydroxy, which can be protected by a protective group, or lower alkoxy, and the said lower alkyl can be substituted by hydroxy, which can be protected by a protective group, amino or lower alkylamino;R.sup.4 is tetrazolyl, phosphonol or lower alkyl ester thereof, or sulfonyl or lower alkyl ester thereof, andA is alkylene.

Abstract: This invention offers the compounds of the formula [I]which are useful for treatment of cataract. ##STR1## wherein R.sup.1 is hydroxy which can be protected by a protective group;R.sup.2 is lower alkyl;R.sup.3 is hydrogen, lower alkyl, hydroxy, which can be protected by a protective group, or lower alkoxy, and the said lower alkyl can be substituted by hydroxy, which can be protected by a protective group, amino or lower alkylamino;R.sup.4 is carboxy which can be converted to ester or amide, andA is alkylene.